ArticleFrontiers in nutrition2025
Association between Prognostic Nutritional Index and myelosuppression in gastric cancer patients undergoing chemotherapy: a retrospective cohort study.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association between pre-treatment malnutrition and chemotherapy toxicity in patients with advanced or metastatic gastroenteric tumors receiving systemic therapy.Frontiers in nutrition · 2026Article
- Interpretable machine-learning prediction of severe myelosuppression in colorectal cancer patients receiving chemotherapy using XGBoost and SHAP: a retrospective study with a web-based calculator.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the association between Prognostic Nutritional Index (PNI) and chemotherapy-induced myelosuppression in gastric cancer patients. Methods: This retrospective cohort study analyzed 562 gastric cancer patients receiving chemotherapy at two Chinese medical centers from January 2022 to December 2024. The exposure variable was PNI, calculated from serum albumin and lymphocyte count. The primary outcome was myelosuppression after the first chemotherapy cycle, defined according to CTCAE 5.0 criteria. Multiple logistic regression models adjusted for demographics, health status, tumor characteristics, treatment factors, and laboratory parameters. Results: Myelosuppression occurred in 75.1% of patients. After full adjustment, each one-unit increase in PNI reduced myelosuppression risk by 13% (OR = 0.87, 95%CI: 0.79-0.96, Conclusion: PNI is an independent predictor of chemotherapy-induced myelosuppression in gastric cancer patients, with a threshold of ≤48 identifying high-risk individuals. This readily available biomarker may guide personalized preventive strategies, particularly for male patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.